Navigating Health Tech Funding: Optimal Timing and Investor Engagement

Join us for the last Masterclass of 2024!

We've assembled a stellar lineup of experts to discuss the funding landscape in Healthtech & Medical Devices. Learn how your value proposition determines the optimal timing and strategies for maximising your chances of success.

What You Will Learn:

Overview and insight on the funding landscape in Health Tech: Government grants, industry growth programs and other funding avenues
Understanding the value proposition of your innovation into market
How to validate the value proposition of your innovation
Why clarity on your market strategy is fundamental to design your trial and regulatory strategy
Fundamentals of regulatory strategy to ensure your product's successful journey
Understanding the criteria and how your value proposition can secure the next stage of funding process
Learn strategies for making the whole funding process smooth for yourself and investors

Agenda:

11:30am: Registration + light lunch networking

12:10pm: Masterclass
1:25pm: Q&A & Panel Discussion
1:50pm: What's next
2:00pm: Event conclude

Meet the Experts:

Prof Mark Flynn (Facilitator)

Principal, Global Edge Medtech Consulting

Prof Mark Flynn is a Professor at the University of Newcastle and the Chief Audiology Officer at Sound Scouts. He is passionate for the development of innovative technology to assist people with hearing loss. Mark has a PhD from the University of Melbourne, a dual MBAs from Georgetown University and ESADE, and won 22 individual and group prizes for his professional work. For his product innovation, he has been responsible for over 20 medical products and services, inventor of 17 international patents, author of over 100 publications, and raised over $74M in grant funding.

Jeremy Chrisp
Founder and Managing Director (Chrisp & Associates)

Jeremy is a highly energetic leader, experienced strategic thinker and implementer of novel and effective solutions in complex life-science and biotechnology development and commercialisation settings. He is the Founder and Managing Director of Chrisp & Associate, specialising in all facets of commercialisation for the Australian biotechnology industry, including provision of CEO services to EpiAxis Therapeutics and consulting services to universities, research institutions and medical device companies.

Jeremy brings a wealth of experience in business and strategic development, investment directorship, evaluation of new technologies, commercial advancement of technologies and the negotiation of transactions for both licensing and acquisitions in the Australian healthcare market for global organisations encompassing pharmaceutical, medical device, diagnostics, consumable and biotechnology asset from early discovery to market.

Anne O'Neil
Director for Enterprise, International Partnerships and Clinical Trials at the Office for Health and Medical Research

Anne has over 25 years’ experience in the health, medical research and policy sectors. She is responsible for leading the development and implementation of major policies and programs to enhance medical research capacity in NSW, and raise the profile of NSW research and development nationally and internationally. She is responsible for the NSW Medical Device Fund and NSW Commercialisation Training Program – both have been critical to accelerating the development of NSW intellectual property and the next generation of innovators and entrepreneurs in NSW. She holds a Bachelor of Science (Physiology and Pharmacology) (Hons) and an Executive Masters of Public Administration.

Kea Dent

Managing Director, KD&A

With over three decades of experience in the medical device sector, Kea possess a wealth of expertise, having worked as both a medical device manufacturer and regulatory consultant. Kea’s journey commenced in 1993 when she setup and managed a medical device manufacturing business. Over the subsequent decade Kea navigated the medical device regulatory landscape firsthand as a device manufacturer, acquiring and upholding numerous product certifications (CE Marking as per the Medical Device Directive 93/42/EEC (obtained in 1998), 510(k) clearance, TGA and Health Canada certifications, etc.) and QMS certifications crucial for market access to over 44 countries.

-----------

Don't miss this opportunity to gain valuable insights from industry experts and network with fellow health tech innovators.

Register now to secure your spot in this must-attend masterclass for health tech entrepreneurs looking to amplify their presence in the market!

Cicada Innovations is proud to be collaborating with the Westmead Health & Innovation District, Australia’s fastest-growing health and innovation precinct, for this commercialisation masterclass series. These masterclasses are to help bridge the gap between research and commercialisation.

Find out more about the Cicada HealthTech Hub

The Cicada HealthTech Hub is proudly supported by NSW Government and is part of the Westmead’s Health & Innovation District. The district includes 4 major hospitals, 4 world-leading medical research institutes, 2 university campuses and the largest research-intensive pathology service in NSW. By 2036, the number of full-time staff will increase to more than 50,000 and the number of students will expand to more than 10,000. Among the first projects for development is a viral vector advanced manufacturing facility to provide ground-breaking trial therapies for infections, cancer and genetic diseases.